鐘愉明 鄧小林 楊忠圣 何小龍 杜傳策 宋樂明
【摘要】 目的:分析智能控壓下輸尿管硬鏡聯(lián)合軟鏡吸引取石術(shù)在復(fù)雜性腎結(jié)石患者中的效果。方法:選取2021年4月—2023年4月贛州市人民醫(yī)院收治的100例復(fù)雜性腎結(jié)石患者,按隨機(jī)數(shù)字表法分為對(duì)照組和觀察組,各50例。對(duì)照組行微創(chuàng)經(jīng)皮腎鏡碎石術(shù),觀察組行智能控壓下輸尿管硬鏡聯(lián)合軟鏡吸引取石術(shù)。對(duì)比兩組圍手術(shù)期指標(biāo)、結(jié)石清除情況、生活質(zhì)量及并發(fā)癥。結(jié)果:觀察組手術(shù)時(shí)間為(79.69±7.59)min,長(zhǎng)于對(duì)照組的(57.21±6.05)min;住院時(shí)間為(4.16±0.69)d,短于對(duì)照組的(6.59±1.38)d;術(shù)后24 h的視覺模擬評(píng)分法(VAS)評(píng)分為(2.35±0.36)分,低于對(duì)照組的(3.21±0.56)分;觀察組并發(fā)癥總發(fā)生率為4.00%(2/50),低于對(duì)照組的18.00%(9/50);觀察組結(jié)石清除率為96.00%(48/50),高于對(duì)照組的84.00%(42/50),差異均有統(tǒng)計(jì)學(xué)意義(P<0.05)。術(shù)前,兩組生活質(zhì)量綜合評(píng)定問卷-74(GQOLI-74)各維度評(píng)分相比,差異均無統(tǒng)計(jì)學(xué)意義(P>0.05);術(shù)后1個(gè)月,觀察組GQOLI-74中的社會(huì)功能、心理功能、軀體功能評(píng)分均高于對(duì)照組,差異均有統(tǒng)計(jì)學(xué)意義(P<0.05);兩組物質(zhì)生活狀態(tài)評(píng)分相比,差異無統(tǒng)計(jì)學(xué)意義(P>0.05)。結(jié)論:智能控壓下輸尿管硬鏡聯(lián)合軟鏡吸引取石術(shù)治療復(fù)雜性腎結(jié)石患者效果顯著,能夠縮短住院時(shí)間,可有效清除患者體內(nèi)結(jié)石,減輕術(shù)后疼痛,利于提升生活質(zhì)量,減少并發(fā)癥。
【關(guān)鍵詞】 復(fù)雜性腎結(jié)石 智能控壓下輸尿管硬鏡聯(lián)合軟鏡吸引取石術(shù) 生活質(zhì)量
Observation on the Effect of Rigid Ureteroscope Combined with Flexible Ureteroscope Suction Lithotomy under Intelligent Control Pressure in the Treatment of Complex Renal Calculus/ZHONG Yuming, DENG Xiaolin, YANG Zhongsheng, HE Xiaolong, DU Chuance, SONG Leming. //Medical Innovation of China, 2023, 20(34): 0-022
[Abstract] Objective: To analyze the effect of rigid ureteroscope combined with flexible ureteroscope suction lithotomy under intelligent control pressure in the treatment of complex renal calculus. Method: A total of 100 patients with complex renal calculus admitted to Ganzhou People's Hospital from April 2021 to April 2023 were selected and divided into the control group and the observation group according to the random number table method, with 50 cases in each group. The control group was treated with minimally invasive percutaneous nephrolithotomy, and the observation group was treated with rigid ureteroscope combined with flexible ureteroscope suction lithotomy under intelligent control pressure. The perioperative indicators, stone clearance, quality of life and complications were compared between the two groups. Result: The operation time was (79.69±7.59) min in the observation group, which was longer than (57.21±6.05) min in the control group; the hospitalization time of the observation group was (4.16±0.69) d, which was shorter than (6.59±1.38) d of the control group; the visual analogue scale (VAS) score of 24 h after operation was (2.35±0.36) points, which was lower than (3.21±0.56) points of the control group; the total incidence of complications in the observation group was 4.00% (2/50), which was lower than 18.00% (9/50) in the control group; the stone clearance rate was 96.00% (48/50) in the observation group, which was higher than 84.00% (42/50) in the control group, the differences were statistically significant (P<0.05). Before operation, there were no statistically significant differences in the scores of each dimension in the general quality of life inventory-74 (GQOLI-74) between the two groups (P>0.05), 1 month after operation, the scores of social function, psychological function and physical function in GQOLI-74 of the observation group were higher than those of the control group, the differences were statistically significant (P<0.05). There was no significant difference in the score of material life status between the two groups (P>0.05). Conclusion: The effect of rigid ureteroscope combined with flexible ureteroscope suction lithotomy under intelligent control pressure is significant in the treatment of complex renal calculus, which can shorten the length of the hospitalization time, effectively remove calculus in the patient's body, reduce postoperative pain, improve the quality of life, and reduce complications.
[Key words] Complex renal calculus Rigid ureteroscope combined with flexible ureteroscope suction lithotomy under intelligent control pressure Quality of Life
First-author's address: Ganzhou People's Hospital, Jiangxi Province, Ganzhou 341000, China
doi:10.3969/j.issn.1674-4985.2023.34.004
腎結(jié)石為臨床常見的泌尿系統(tǒng)疾病,多因體內(nèi)鈣磷代謝異常、飲食習(xí)慣等多種原因相互作用引起的腎盂內(nèi)鈣鹽沉積,患者常表現(xiàn)出腰背疼痛等癥狀,臨床患病率較高[1-2]。復(fù)雜性腎結(jié)石則是指結(jié)石成分、大小、形狀等參數(shù)復(fù)雜多樣的腎結(jié)石,包括孤立腎結(jié)石、異位性腎結(jié)石等[3-4]。近年來,因人們生活習(xí)慣的轉(zhuǎn)變,復(fù)雜性腎結(jié)石的患病人數(shù)不斷增加,給患者身心健康造成嚴(yán)重影響[5]。手術(shù)為目前臨床治療的常見手段,其中以微創(chuàng)經(jīng)皮腎鏡碎石術(shù)較為常見,但該手術(shù)會(huì)損傷腎實(shí)質(zhì),容易誘發(fā)腎出血等并發(fā)癥,不利于患者術(shù)后恢復(fù)。隨著醫(yī)學(xué)技術(shù)的快速發(fā)展,輸尿管硬鏡聯(lián)合軟鏡吸引取石術(shù)的出現(xiàn)為臨床治療復(fù)雜性腎結(jié)石提供了新的方向,但在碎石過程中容易出現(xiàn)腎盂內(nèi)高壓、誘發(fā)膿毒血癥等并發(fā)癥。贛州市人民醫(yī)院結(jié)合臨床實(shí)踐,創(chuàng)新發(fā)現(xiàn)智能控壓下輸尿管硬鏡聯(lián)合軟鏡吸引取石術(shù),可達(dá)到精準(zhǔn)監(jiān)控腎盂內(nèi)壓力的效果,但臨床尚缺乏相關(guān)報(bào)道?;诖耍狙芯恳?021年4月—2023年4月本院收治的100例復(fù)雜性腎結(jié)石患者為研究對(duì)象,探究該手術(shù)的具體效果,現(xiàn)報(bào)道如下。
1 資料與方法
1.1 一般資料
選取2021年4月—2023年4月本院收治的100例復(fù)雜性腎結(jié)石患者為研究對(duì)象。納入標(biāo)準(zhǔn):(1)經(jīng)CT等檢查明確病情;(2)符合手術(shù)指征;(3)認(rèn)知功能正常。排除標(biāo)準(zhǔn):(1)惡性腫瘤;(2)存在傳染性疾??;(3)伴有凝血功能紊亂;(4)存在自身免疫性疾?。唬?)嚴(yán)重心、肝功能不全;(6)術(shù)前腎功能明顯受損;(7)妊娠期或哺乳期;(8)輸尿管狹小扭曲;(9)存在嚴(yán)重精神障礙;(10)合并全身性感染。按隨機(jī)數(shù)字表法分為觀察組和對(duì)照組,各50例。研究經(jīng)本院醫(yī)學(xué)倫理委員會(huì)批準(zhǔn),患者均知情同意本研究。
1.2 方法
對(duì)照組行微創(chuàng)經(jīng)皮腎鏡碎石術(shù)。全麻,患者取截石位,逆行置入輸尿管導(dǎo)管,之后轉(zhuǎn)變患者體位成俯臥位。在B超下穿刺,構(gòu)建經(jīng)皮通道,置入16Fr吸引鞘,采用鈥激光進(jìn)行碎石,能量設(shè)為2.0~2.5 J,頻率設(shè)為20 Hz;留置雙J管。觀察組行智能控壓下輸尿管硬鏡聯(lián)合軟鏡吸引取石術(shù)。首先通過智能控壓輸尿管硬鏡吸引取石治療腎盂與部分中上盞結(jié)石,全麻,取健側(cè)斜仰臥位,在F7輸尿管硬鏡(德國storz公司)直視下將斑馬導(dǎo)絲送入到結(jié)石下方并進(jìn)行鏡檢,確定無顯著狹窄與輸尿管扭曲之后,上鏡到腎盂,以硬鏡檢查結(jié)石,若確定結(jié)石位置后行碎石術(shù);于斑馬導(dǎo)絲下放入F12/14吸引鞘,置入硬鏡確定吸引鞘前端處在輸尿管結(jié)石峽部0.5 cm區(qū)域,吸引鞘測(cè)壓接口、吸引接口分別通過壓力傳感器和吸引管同平臺(tái)連接;測(cè)壓傳感系統(tǒng)在注水之后通過平臺(tái)校零,模式為全自動(dòng)模式,術(shù)中腔內(nèi)壓、警戒值、極限值分別設(shè)為-15~-5、20、30 mmHg,灌注流量為50~150 mL/min,選用550 μm鈥激光碎石,功率設(shè)為1.0~2.0 J,20~30 Hz;第二階段通過智能控壓輸尿管軟鏡吸引取石治療殘余結(jié)石,術(shù)中選用200 μm鈥激光光纖碎石,功率為0.6~0.8 J,20~30 Hz,碎石過程中,鏡體在鞘內(nèi)不間斷的活動(dòng),調(diào)控前后移動(dòng)距離為2~3 mm,留置雙J管。兩組手術(shù)之后均給予抗生素等常規(guī)治療及護(hù)理,持續(xù)觀察1個(gè)月。
1.3 觀察指標(biāo)及評(píng)價(jià)標(biāo)準(zhǔn)
(1)結(jié)石清除情況:術(shù)后1個(gè)月,復(fù)查CT,統(tǒng)計(jì)兩組結(jié)石清除情況,殘余結(jié)石<3 mm判定為結(jié)石清除,比較兩組結(jié)石清除率。(2)圍手術(shù)期指標(biāo):包括手術(shù)時(shí)間、住院時(shí)間及疼痛程度。術(shù)后24 h,以視覺模擬評(píng)分法(VAS)評(píng)估疼痛程度,量表共10分,分?jǐn)?shù)高,疼痛重[6]。(3)生活質(zhì)量:分別于術(shù)前、術(shù)后1個(gè)月使用生活質(zhì)量綜合評(píng)定問卷-74(GQOLI-74)評(píng)估,量表共4個(gè)維度,滿分均100分,分?jǐn)?shù)越高越好[7]。(4)并發(fā)癥:包括出血、感染、發(fā)熱和輸尿管損傷,比較兩組并發(fā)癥總發(fā)生率。
1.4 統(tǒng)計(jì)學(xué)處理
示,比較采用t檢驗(yàn);計(jì)數(shù)資料以率(%)表示,比較采用χ2檢驗(yàn)。以P<0.05為差異有統(tǒng)計(jì)學(xué)意義。
2 結(jié)果
2.1 兩組一般資料對(duì)比
兩組一般資料對(duì)比,差異均無統(tǒng)計(jì)學(xué)意義(P>0.05),具有可比性,見表1。
2.2 兩組結(jié)石清除率對(duì)比
觀察組術(shù)后1個(gè)月的結(jié)石清除率為96.00%(48/50),高于對(duì)照組的84.00%(42/50),差異有統(tǒng)計(jì)學(xué)意義(χ2=4.000,P=0.046)。
2.3 兩組圍手術(shù)期指標(biāo)對(duì)比
觀察組手術(shù)時(shí)間長(zhǎng)于對(duì)照組,住院時(shí)間短于對(duì)照組,術(shù)后24 h的VAS評(píng)分低于對(duì)照組,差異均有統(tǒng)計(jì)學(xué)意義(P<0.05),見表2。
2.4 兩組GQOLI-74評(píng)分對(duì)比
術(shù)前,兩組GQOLI-74各維度評(píng)分相比,差異均無統(tǒng)計(jì)學(xué)意義(P>0.05);術(shù)后1個(gè)月,觀察組GQOLI-74中的社會(huì)功能、心理功能、軀體功能評(píng)分均高于對(duì)照組,差異均有統(tǒng)計(jì)學(xué)意義(P<0.05);兩組物質(zhì)生活狀態(tài)評(píng)分比較,差異無統(tǒng)計(jì)學(xué)意義(P>0.05)。見表3。
2.5 兩組并發(fā)癥總發(fā)生率對(duì)比
觀察組并發(fā)癥總發(fā)生率低于對(duì)照組,差異有統(tǒng)計(jì)學(xué)意義(χ2=5.005,P=0.025),見表4。
3 討論
復(fù)雜性腎結(jié)石為臨床常見的泌尿系統(tǒng)疾病之一,多為直徑≥2.5 cm的腎多發(fā)結(jié)石,包括鹿角形結(jié)石、多發(fā)性腎結(jié)石等[8-9]。復(fù)雜性腎結(jié)石患者常表現(xiàn)出腰部鈍痛、酸脹等表現(xiàn),嚴(yán)重降低其生活質(zhì)量[10-11]。因此,探尋快速有效的措施治療復(fù)雜性腎結(jié)石,及時(shí)清除患者體內(nèi)結(jié)石,對(duì)于改善預(yù)后具有重要意義[12-13]。
對(duì)于此類患者,目前臨床以微創(chuàng)經(jīng)皮腎鏡碎石術(shù)為主要治療手段,該手術(shù)可有效清除患者體內(nèi)結(jié)石,在臨床應(yīng)用較為廣泛[14-15]。但其術(shù)中需構(gòu)建通道,容易對(duì)腎實(shí)質(zhì)造成損傷,從而誘發(fā)并發(fā)癥,給患者術(shù)后恢復(fù)造成較大影響[16-17]。近年,隨著外科手術(shù)的不斷進(jìn)步及對(duì)復(fù)雜性腎結(jié)石研究的不斷深入,臨床研發(fā)出了輸尿管硬鏡聯(lián)合軟鏡吸引取石術(shù)。輸尿管硬鏡聯(lián)合軟鏡吸引取石術(shù)將硬鏡的高效率與軟鏡的靈活可彎曲轉(zhuǎn)動(dòng)優(yōu)勢(shì)相互結(jié)合,達(dá)到高效率、低風(fēng)險(xiǎn)、低成本的目標(biāo)效果[18-19]。然而,術(shù)中醫(yī)師為獲得清晰的視野會(huì)增加灌注流量,易誘發(fā)腎盂內(nèi)高壓,增加腎膿毒血癥與腎出血的發(fā)生風(fēng)險(xiǎn)[20],反之,術(shù)中若灌注量較低,容易造成視野不清晰,腎內(nèi)液體循環(huán)缺乏。連續(xù)長(zhǎng)時(shí)間的激發(fā)鈥激光會(huì)導(dǎo)致腎盂黏膜熱損傷,進(jìn)而對(duì)患者的腎功能造成損傷。因此,對(duì)腎盂內(nèi)壓進(jìn)行積極的控制至關(guān)重要。本研究結(jié)果顯示,觀察組手術(shù)時(shí)間長(zhǎng)于對(duì)照組,住院時(shí)間短于對(duì)照組,術(shù)后24 h的VAS評(píng)分低于對(duì)照組,結(jié)石清除率高于對(duì)照組,并發(fā)癥總發(fā)生率低于對(duì)照組;且術(shù)后的GQOLI-74內(nèi)社會(huì)功能、心理功能、軀體功能評(píng)分均高于對(duì)照組。提示,智能控壓下輸尿管硬鏡聯(lián)合軟鏡吸引取石術(shù)能夠縮短住院時(shí)間,緩解疼痛,利于患者生活質(zhì)量的提升,且并發(fā)癥較少。觀察組手術(shù)時(shí)間較長(zhǎng)的原因可能與置鞘、裝機(jī)等過程耗費(fèi)時(shí)間有關(guān)。同時(shí),智能控壓裝置能夠自動(dòng)監(jiān)測(cè)、控制腎盂內(nèi)壓,利于手術(shù)醫(yī)師在手術(shù)期間更為良好的掌握患者的腎盂內(nèi)壓,可滿足連續(xù)碎石所需的灌注量,由此確保術(shù)中視野清晰,進(jìn)而提高結(jié)石清除效率[21]。智能控壓裝置可在鈥激光碎石的同時(shí)高效率自動(dòng)吸引出結(jié)石,極大程度的減少術(shù)后殘石,進(jìn)一步提升結(jié)石清除率。另外,智能控壓裝置可有效控制腔內(nèi)壓力,避免因輸尿管鏡頻繁進(jìn)出輸尿管而引起的損傷,從而減輕術(shù)后疼痛,減少并發(fā)癥發(fā)生風(fēng)險(xiǎn),促進(jìn)術(shù)后恢復(fù),改善生活質(zhì)量。本研究所納入的樣本量較少,可能會(huì)對(duì)本研究結(jié)果的準(zhǔn)確度造成一定影響,因此,臨床還需不斷完善研究設(shè)計(jì),擴(kuò)充樣本量,更全面地了解智能控壓下輸尿管硬鏡聯(lián)合軟鏡吸引取石術(shù)治療復(fù)雜性腎結(jié)石的有效性,為臨床提供更可靠的參考信息,改善患者預(yù)后。
綜上所述,智能控壓下輸尿管硬鏡聯(lián)合軟鏡吸引取石術(shù)在復(fù)雜性腎結(jié)石治療中效果顯著,住院時(shí)間更短,能夠減輕患者術(shù)后疼痛,提升生活質(zhì)量及減少并發(fā)癥。
參考文獻(xiàn)
[1] AN L,XIONG L,CHEN L,et al.Concomitant treatment of ureteropelvic junction obstruction complicated by renal calculi with laparoscopic pyeloplasty and pyelolithotomy via 19.5F rigid nephroscope:a report of 12 cases[J].J Invest Surg,2022,35(1):77-82.
[2] ALI S N,MORGAN K,BHATT R,et al.Retrograde cystonephroscopy for complex renal calculi using novel dual-action aspiration,irrigation cystoscope:initial case series[J].J Endourol,2022,36(7):898-905.
[3] ZHU H,ZHAO Z,CHENG D,et al.Multiple-tract percutaneous nephrolithotomy as a day surgery for the treatment of complex renal stones:an initial experience[J].World J Urol,2021,39(3):921-927.
[4]王培龍,李笑然,何藄琪,等.單通道經(jīng)皮腎鏡取石術(shù)聯(lián)合輸尿管軟鏡與輸尿管軟鏡鈥激光碎石術(shù)治療復(fù)雜性腎結(jié)石的效果比較[J].實(shí)用臨床醫(yī)藥雜志,2023,27(2):101-104,112.
[5]徐曉健,張俊,陳宗薪,等.微通道經(jīng)皮腎鏡聯(lián)合輸尿管軟鏡與輸尿管軟鏡鈥激光碎石術(shù)治療復(fù)雜腎結(jié)石療效及對(duì)腎功能的影響[J].臨床和實(shí)驗(yàn)醫(yī)學(xué)雜志,2022,21(3):313-317.
[6]段成斌,王資斌.輸尿管軟鏡鈥激光碎石術(shù)與微創(chuàng)經(jīng)皮腎鏡碎石術(shù)治療2~3 cm腎結(jié)石的效果及安全性比較[J].實(shí)用醫(yī)院臨床雜志,2022,19(4):128-131.
[7]李凌江,楊德森,周亮,等.世界衛(wèi)生組織生活質(zhì)量問卷在中國應(yīng)用的信度及效度研究[J].中華精神科雜志,2003,36(3):143-147.
[8]王磊,羅子靖,魏洪亮,等.微通道經(jīng)皮腎鏡Cyberwand超聲碎石術(shù)治療復(fù)雜性腎結(jié)石的療效[J].現(xiàn)代泌尿外科雜志,2021,26(10):812-815.
[9]何青松,謝永煌,黃德勇,等.微創(chuàng)經(jīng)皮腎鏡鈥激光碎石術(shù)對(duì)復(fù)雜性腎結(jié)石患者血清及尿液腎損傷指標(biāo)的影響研究[J].中國醫(yī)學(xué)創(chuàng)新,2022,19(12):30-34.
[10] ZHANG J,XIAO N,HUANG K,et al.Effect of percutaneous nephrolithotripsy under guidance of B-ultrasound for the treatment of complex renal calculi[J].J Pak Med Assoc,2022,72(6):1198-1200.
[11] MOUSAWI SA,GUZEL R,ZAID M,et al.Minipercutaneous nephrolithotomy in the management of large and complex renal calculi in children:how effective is it?[J].J Endourol,2023,37(4):387-393.
[12]孫文龍.經(jīng)皮腎鏡鈥激光碎石術(shù)對(duì)復(fù)雜性腎結(jié)石患者尿液炎癥及腎損傷指標(biāo)的影響研究[J].中國醫(yī)學(xué)創(chuàng)新,2021,18(5):25-28.
[13]賴錦源,盧凱鑫,劉昌毅,等.腎臟incool-3D立體影像技術(shù)在復(fù)雜腎結(jié)石經(jīng)皮腎鏡碎石取石術(shù)中的應(yīng)用:前瞻性隨機(jī)對(duì)照研究[J].中國微創(chuàng)外科雜志,2021,21(9):776-781.
[14]余子強(qiáng),徐久平,詹長(zhǎng)生,等.輸尿管軟鏡碎石與經(jīng)皮腎鏡碎石對(duì)3 cm以下腎結(jié)石療效和炎性反應(yīng)的影響[J].基礎(chǔ)醫(yī)學(xué)與臨床,2022,42(8):1259-1262.
[15]張光耀.微通道經(jīng)皮腎鏡取石術(shù)聯(lián)合輸尿管軟鏡鈥激光碎石術(shù)治療復(fù)雜腎結(jié)石的效果觀察[J].中國臨床醫(yī)生雜志,2022,50(10):1196-1198.
[16]張朝陽,周艦,楊軍,等.側(cè)臥位單通道微創(chuàng)經(jīng)皮腎鏡取石術(shù)與輸尿管軟鏡碎石術(shù)治療成人腎結(jié)石臨床效果比較[J].臨床軍醫(yī)雜志,2021,49(7):791-792.
[17]闞宗泉,王展,金志波,等.改良彎曲俯臥位經(jīng)皮腎鏡手術(shù)對(duì)復(fù)雜性腎結(jié)石患者血流動(dòng)力學(xué)和舒適度的影響[J].中國實(shí)用護(hù)理雜志,2021,37(8):573-578.
[18]鄭濤.輸尿管硬鏡聯(lián)合軟鏡鈥激光碎石術(shù)治療復(fù)雜性輸尿管上段結(jié)石患者的效果[J].中外醫(yī)學(xué)研究,2022,20(34):145-149.
[19]鄭浩.輸尿管硬鏡聯(lián)合軟鏡治療復(fù)雜性輸尿管上段結(jié)石的療效觀察[J].淮海醫(yī)藥,2019,37(5):448-450,453.
[20]葉根恒.經(jīng)自然腔道的輸尿管硬鏡聯(lián)合軟鏡治療2 cm以上腎結(jié)石的療效、疼痛程度及血紅蛋白分析[J].數(shù)理醫(yī)藥學(xué)雜志,2022,35(9):1305-1307.
[21]何忠南.智能控壓輸尿管軟鏡吸引取石術(shù)治療腎結(jié)石的臨床效果研究[J].中國實(shí)用醫(yī)藥,2021,16(16):67-69.
(收稿日期:2023-09-25) (本文編輯:郝天煜)
*基金項(xiàng)目:江西省衛(wèi)生健康委科技計(jì)劃項(xiàng)目(SKJP220211020)
①江西省贛州市人民醫(yī)院 江西 贛州 341000
通信作者:鐘愉明